Data / New clinical trials / Industry sponsors
Industry-sponsored trials: 15,160 new
The full list. New industry-sponsored clinical trials: 15,160 rows for $231.60, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 680 rows a month. The new rows come each week by email, $34 a month.
Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.
For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/sponsor/industry, and every list with its row count and price is at https://specstream.ai/data/lists.json.
Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).
15,160 clinical studies with a lead sponsor of class industry were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 15,160 have an industry sponsor and 9,775 are recruiting or about to. The newest, NCT07927088, was posted on November 9, 2026: Halova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal Women (Perfect Care Distribution).
The request: Every new industry-sponsored clinical trial on ClinicalTrials.gov, with the sponsor, phase, conditions and the listed contact. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.
- 15,160New trials
- 15,160Industry sponsored
- 9,775Recruiting or not yet
- November 9, 2026Latest posted
Newest trials
The newest 100 of 15,160, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.
| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
|---|---|---|---|---|---|---|---|---|---|
| November 9, 2026 | NCT07927088 | Halova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal Women | Perfect Care Distribution | Not applicable | Completed | Vaginal Dryness, Genitourinary Symptoms | 150 | Romania | clinicaltrials.gov |
| November 9, 2026 | NCT07927023 | A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | Pfizer | Observational | Not yet recruiting | Multiple Myeloma | 1 | clinicaltrials.gov | |
| November 9, 2026 | NCT07927010 | A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related... | Mighty Therapeutics, Inc. | Phase 2/3 | Not yet recruiting | Dry AMD, Age-Related Macular Degeneration (AMD) | 300 | clinicaltrials.gov | |
| November 9, 2026 | NCT07926737 | CMT-133 in Healthy Adult Participants | Clement Therapeutics, Inc. | Phase 1 | Not yet recruiting | Healthy Adult Participants | 64 | clinicaltrials.gov | |
| November 9, 2026 | NCT07926581 | Study Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing Approval | FUSMobile Inc. | Observational | Not yet recruiting | Lumbar Zygapophyseal Pain, Low Back Pain, Facet Joint Pain; Low Back Pain | 60 | Spain | clinicaltrials.gov |
| November 9, 2026 | NCT07926425 | Retrospective Evaluation of Visual Outcomes, Safety and Enhancement Rates Following Wavefront-Guided LASIK Using a 10 MHz Elita Femtosecond... | CB Consulting | Observational | Recruiting | Visual Acuity | 175 | United States | clinicaltrials.gov |
| November 9, 2026 | NCT07926386 | Interventional Study to Describe the Utilization of Foam Dressings in Routine Clinical Practice, for the Treatment of Patients With Chronic... | Molnlycke Health Care AB | Not applicable | Recruiting | Chronic Wound Care | 40 | Italy | clinicaltrials.gov |
| November 9, 2026 | NCT07926334 | A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 200 | Australia, Japan, South Korea, Spain, United States | clinicaltrials.gov |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | Belgium, Finland, Germany, Japan, Mexico, South Korea, Spain, United States | clinicaltrials.gov |
| November 9, 2026 | NCT07926308 | Real-world Outcome of Zongertinib in Japan (J-HERZ) | Boehringer Ingelheim | Observational | Not yet recruiting | Non-small Cell Lung Cancer | 300 | Japan | clinicaltrials.gov |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 | clinicaltrials.gov | |
| November 9, 2026 | NCT07925983 | A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants | AbbVie | Phase 1 | Recruiting | Healthy Volunteer | 60 | United States | clinicaltrials.gov |
| November 9, 2026 | NCT07925853 | Bioavailability of Two Mitopure Formulations | Amazentis SA | Not applicable | Not yet recruiting | Healthy Adults | 24 | clinicaltrials.gov | |
| November 9, 2026 | NCT07925775 | Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and Above | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 | Not yet recruiting | Lower Respiratory Tract Disease Caused by RSV Infection | 96 | clinicaltrials.gov | |
| November 9, 2026 | NCT07925619 | Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers | Pharmosa Biopharm Inc. | Phase 2 | Not yet recruiting | Systemic Sclerosis | 40 | clinicaltrials.gov | |
| November 9, 2026 | NCT07925502 | Post Market Clinical Follow-Up Registry Study of the aXess Hemodialysis Conduit | Xeltis | Not applicable | Not yet recruiting | End Stage Renal Failure, Hemodialysis | 350 | clinicaltrials.gov | |
| November 9, 2026 | NCT07925359 | The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed... | Boston Scientific Corporation | Not applicable | Not yet recruiting | Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation (PersAF), FARAPULSE | 200 | Croatia, Czechia, France | clinicaltrials.gov |
| November 9, 2026 | NCT07925216 | A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting Conditions | Triastek, lnc. | Phase 1 | Active not recruiting | IgA Nephropathy (IgAN) | 18 | China | clinicaltrials.gov |
| November 9, 2026 | NCT07925190 | A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Acute Myeloblastic Leukaemia | 318 | China | clinicaltrials.gov |
| November 9, 2026 | NCT07925034 | PREFIX FEASIBILITY Study - PRojection & Safety Evaluation of the FIXNip Nipple Reconstruction Implant | FixNip Ltd | Not applicable | Recruiting | Breast Reconstruction After Mastectomy | 5 | United States | clinicaltrials.gov |
| November 9, 2026 | NCT07925021 | A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | 424 | China | clinicaltrials.gov |
| November 9, 2026 | NCT07925008 | Clinical Study on the Safety and the Performance of an Endometrial Ablation System in Women With Abnormal Uterine Bleeding (AUB) and... | Aqua Therapeutics, Inc. | Not applicable | Recruiting | Menorrhagia | 15 | Austria, Italy | clinicaltrials.gov |
| November 9, 2026 | NCT07924956 | Explore the Weight Loss Effect of Amway "BODY TRIMMER" | Amway (China) R&D Center | Not applicable | Recruiting | Abdominal Obesity | 110 | China | clinicaltrials.gov |
| November 9, 2026 | NCT07924930 | A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney Function | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | Phase 1 | Not yet recruiting | Renal Insufficiency, Healthy Participant | 32 | United States | clinicaltrials.gov |
| November 9, 2026 | NCT07924761 | A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living... | Kailera | Phase 1 | Not yet recruiting | Overweight or Obesity | 60 | United States | clinicaltrials.gov |
| November 9, 2026 | NCT07924462 | Chronic Respiratory Disease Participant Engagement Study | Richmond Research Institute | Observational | Recruiting | Interstitial Lung Disease (ILD), Chronic Respiratory Diseases, Alpha-1 Antitrypsin Deficiency (AATD), Chronic... | 500 | United Kingdom | clinicaltrials.gov |
| November 9, 2026 | NCT07924397 | A Study to Assess IG001643 in Healthy Participants | Iongen Therapeutics Co., Ltd. | Phase 1 | Not yet recruiting | Pain Management | 86 | New Zealand | clinicaltrials.gov |
| November 9, 2026 | NCT07924345 | Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia Patients | HK inno.N Corporation | Observational | Recruiting | Dyslipidemia | 6,713 | South Korea | clinicaltrials.gov |
| November 9, 2026 | NCT07924293 | A Study to Evaluate the Acceptability of the FemBloc System as a Non-surgical, Permanent Contraceptive Method | Femasys Inc. | Observational | Active not recruiting | Contraception | 200 | Spain | clinicaltrials.gov |
| November 9, 2026 | NCT07924267 | A Single Ascending Dose and Multiple Ascending Dose Trial to Assess the Dose, the Efficacy and Oro-sensitivity of Two Modified Linoleic... | EktaH | Phase 1 | Completed | Obesity & Overweight, Overweight (BMI > 30) | 120 | Tunisia | clinicaltrials.gov |
| November 9, 2026 | NCT07924111 | A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 585 | clinicaltrials.gov | |
| November 9, 2026 | NCT07924059 | Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia | Ascendis Pharma A/S | Phase 3 | Not yet recruiting | Achondroplasia | 144 | clinicaltrials.gov | |
| November 9, 2026 | NCT07923981 | A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors | Pfizer | Phase 3 | Recruiting | Hemophilia A or B | 95 | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07923851 | A Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Not yet recruiting | Palmoplantar Pustulosis of Adults | 40 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07923773 | Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) | Novartis Pharmaceuticals | Phase 2 | Not yet recruiting | Moderate to Severe Psoriatic Arthritis | 88 | clinicaltrials.gov | |
| November 6, 2026 | NCT07923747 | An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE) | Novartis Pharmaceuticals | Phase 1 | Not yet recruiting | Rheumatoid Arthritis and Systemic Lupus Erythematosus | 90 | clinicaltrials.gov | |
| November 6, 2026 | NCT07923734 | Study of Electrocardiogram (ECG) Safety of Sezaby in Neonatal Seizures | Sun Pharma Advanced Research Company Limited | Phase 4 | Not yet recruiting | Neonatal Seizure | 45 | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07923591 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 40 | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07923578 | Pharmacokinetics, Safety and Tolerability of Single Sequential and Multiple Intravenous Infusions of Ulinastatin for Injection in Healthy... | Techpool Bio-Pharma Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Participants, Ulinastatin | 40 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07923565 | CANLINK: Evaluation of the Intralink Intradiscal Device for Low Back Pain Due to Degenerative Disc Disease | Spinal Simplicity LLC | Not applicable | Not yet recruiting | Degenerative Disc Disease(DDD) | 40 | Canada | clinicaltrials.gov |
| November 6, 2026 | NCT07923526 | An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic... | United Therapeutics | Phase 2/3 | Not yet recruiting | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | 400 | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07923487 | Pilot Safety and Exploratory Efficacy of PSC-05 for the Treatment of Chronic Mild Traumatic Brain Injury | Personalized Stem Cells, Inc. | Phase 1 | Enrolling by invitation | Mild Traumatic Brain Injury | 10 | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07923383 | An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates | Sanofi | Phase 1 | Not yet recruiting | Ulcerative Colitis, Crohn's Disease | 25 | clinicaltrials.gov | |
| November 6, 2026 | NCT07923357 | A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM | 364 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07923305 | Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and... | Sanofi | Phase 2/3 | Not yet recruiting | Immunodeficiency Common Variable | 96 | clinicaltrials.gov | |
| November 6, 2026 | NCT07923214 | A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors | Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors | 30 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07923097 | Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable. | Rapport Therapeutics Inc. | Phase 1 | Recruiting | Epilepsy | 60 | Australia | clinicaltrials.gov |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | clinicaltrials.gov | |
| November 6, 2026 | NCT07923058 | Clinical Trial of SEEG for Drug-resistant Epilepsy | Beijing Pins Medical Co., Ltd | Not applicable | Not yet recruiting | Drug-Resistant Epilepsy | 99 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07923045 | A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1... | Viatris Inc. | Phase 1/2 | Recruiting | Neurotrophic Keratopathy | 18 | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07922798 | A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy... | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Not yet recruiting | Overweight , Obesity | 60 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07922733 | EXPANDED-ACCESS PROGRAM FOR THE TREATMENT OF CHRONIC HEPATITIS D WITH BRELOVITUG | Mirum Pharmaceuticals, Inc. | Not applicable | Available | Chronic Hepatitis, Delta Virus | Not listed | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07922564 | An Open-label, Randomized, Single Oral Dose, Two-period, Two-sequence, Two-way, Crossover Bioequivalence Study on Healthy Adult Male... | Zi Diligence Biocenter | Phase 1 | Completed | Bioequivalence, Male | 30 | Egypt | clinicaltrials.gov |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | China, India | clinicaltrials.gov |
| November 6, 2026 | NCT07922187 | Speech Recognition With Hearing Enhancement | Meta Platforms Technologies LLC | Not applicable | Completed | Hearing | 43 | United States | clinicaltrials.gov |
| November 6, 2026 | NCT07922174 | A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Healthy, Renal Impairment | 32 | clinicaltrials.gov | |
| November 6, 2026 | NCT07922161 | Smartphone Camera Measurement of Breathing-Related Heart Rate Variability Compared With ECG in Healthy Adults | BELL Therapeutics Inc. | Not applicable | Not yet recruiting | Respiratory Sinus Arrhythmia, Heart Rate Variability, Healthy Volunteers | 36 | South Korea | clinicaltrials.gov |
| November 6, 2026 | NCT07922096 | A First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid Tumors | Chengdu SciMount Pharmatech Co., Ltd. | Phase 1 | Completed | HER2-Expressing Advanced Solid Tumors, HER2-Mutated Advanced Solid Tumors, Metastatic Solid Tumors | 35 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07921966 | Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants | Neurelis, Inc. | Phase 1 | Not yet recruiting | Healthy Adult Participants | 24 | clinicaltrials.gov | |
| November 6, 2026 | NCT07921641 | Characterization of Adaptive Immune Responses to Oropouche Virus (OROV) Infection | Institut Pasteur | Observational | Not yet recruiting | Oropouche Infection | 80 | clinicaltrials.gov | |
| November 6, 2026 | NCT07921576 | Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia | Dartsbio Pharmaceuticals Ltd. | Phase 1/2 | Recruiting | Cancer, Cachexia | 58 | Australia | clinicaltrials.gov |
| November 6, 2026 | NCT07921420 | MF-300 for Treatment of Age-Related Sarcopenia | Epirium Bio Inc. | Phase 2 | Not yet recruiting | Sarcopenia in Elderly | 225 | clinicaltrials.gov | |
| November 6, 2026 | NCT07921316 | Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous... | Amgen | Phase 1 | Not yet recruiting | Obesity, Overweight | 356 | clinicaltrials.gov | |
| November 6, 2026 | NCT07920939 | Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Type 2 Diabetes | 450 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07920926 | Hypothermic Kidney Machine Perfusion With Omnisol | Vivalyx GmbH | Not applicable | Not yet recruiting | End Stage Renal Disease (ESRD), Kidney Transplant, Kidney Failure, Renal and Urinary Tract Therapeutic Procedures | 16 | clinicaltrials.gov | |
| November 6, 2026 | NCT07920887 | A Study of Bimagrumab in Participants With HFpEF | Eli Lilly and Company | Phase 2 | Not yet recruiting | Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction, Heart Failure, Preserved... | 540 | Hungary, Italy, Poland, United States | clinicaltrials.gov |
| November 6, 2026 | NCT07920861 | A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight... | Huabo Biopharm Co., Ltd. | Phase 1 | Recruiting | Psoriasis, Ankylosing Spondylitis | 90 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07920835 | A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Phase 2 | Recruiting | Soft Tissue Sarcoma | 60 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07920822 | Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | Phase 1 | Enrolling by invitation | Soft Tissue Sarcoma, Non-small Cell Lung Cancer | 12 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07920809 | A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Dermatitis Atopic | 60 | clinicaltrials.gov | |
| November 6, 2026 | NCT07920783 | A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 124 | China | clinicaltrials.gov |
| November 6, 2026 | NCT07920679 | Efficacy and Safety of K-CAB(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD | HK inno.N Corporation | Observational | Recruiting | Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD) | 12,868 | South Korea | clinicaltrials.gov |
| November 5, 2026 | NCT07920640 | Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Diabetes Mellitus, Type 2 | 150 | China | clinicaltrials.gov |
| November 5, 2026 | NCT07920484 | A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral... | Amber Implants B.V. | Observational | Recruiting | Vertebra Compression Fracture | 30 | United States | clinicaltrials.gov |
| November 5, 2026 | NCT07920315 | Remibrutinib in Real-world Clinical Practice - a South Korea Sub-Study | Novartis Pharmaceuticals | Observational | Not yet recruiting | Chronic Spontaneous Urticaria | 578 | clinicaltrials.gov | |
| November 5, 2026 | NCT07920263 | Assessment of Binocular Vision Function With Neos™ (ROCKET) | machineMD AG | Not applicable | Not yet recruiting | Binocular Vision Dysfunction | 184 | clinicaltrials.gov | |
| November 5, 2026 | NCT07920211 | Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo | Teva Branded Pharmaceutical Products R&D LLC | Phase 2/3 | Not yet recruiting | Vitiligo | 1,020 | clinicaltrials.gov | |
| November 5, 2026 | NCT07920185 | A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia in a Randomized, Controlled, Dose-finding Study | Somnum Pharma Inc. | Phase 2 | Not yet recruiting | Chronic Insomnia | 45 | United States | clinicaltrials.gov |
| November 5, 2026 | NCT07920172 | Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Recruiting | Herpes Zoster | 500 | China | clinicaltrials.gov |
| November 5, 2026 | NCT07919990 | Effectiveness of Sequential Monopolar and Bipolar Radiofrequency Device for Facial Rejuvenation in Female Participants | Cutis Medical Laser Clinics Pte Ltd | Not applicable | Completed | Skin Laxity | 14 | Singapore | clinicaltrials.gov |
| November 5, 2026 | NCT07919899 | Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation | Sanofi | Phase 3 | Not yet recruiting | Dermatitis Atopic | 150 | clinicaltrials.gov | |
| November 5, 2026 | NCT07919782 | Study to Evaluate Xtressé Gummy Supplement in Women With Thinning Hair | Restore Biologics Holdings, Inc. dba Xtressé | Not applicable | Not yet recruiting | Androgenetic Alopecia | 30 | United States | clinicaltrials.gov |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | Canada, United States | clinicaltrials.gov |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany... | clinicaltrials.gov |
| November 5, 2026 | NCT07919366 | TRI-SUCCESS - Tricuspid Regurgitation Study of the Unica™ Cross-Caval System for the Evaluation of Efficacy and Safety in Significant TR... | Innoventric LTD | Not applicable | Not yet recruiting | Tricuspid Regurgitation, Tricuspid Regurgitation Functional | 510 | clinicaltrials.gov | |
| November 5, 2026 | NCT07919314 | A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval... | Kyorin Pharmaceutical Co.,Ltd | Phase 1 | Recruiting | Healthy Participants | 40 | Canada | clinicaltrials.gov |
| November 5, 2026 | NCT07919210 | A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy... | ModernaTX, Inc. | Phase 1 | Not yet recruiting | Marburg Virus Disease (MVD) | 64 | United Kingdom | clinicaltrials.gov |
| November 5, 2026 | NCT07919197 | A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of Age | ModernaTX, Inc. | Phase 1 | Not yet recruiting | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | 224 | Uganda | clinicaltrials.gov |
| November 5, 2026 | NCT07919028 | A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Healthy | 24 | clinicaltrials.gov | |
| November 5, 2026 | NCT07918898 | Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous... | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Healthy Participants | 26 | clinicaltrials.gov | |
| November 5, 2026 | NCT07918859 | A Study of Imlunestrant (LY3484356) in Healthy Female Participants | Eli Lilly and Company | Phase 1 | Not yet recruiting | Healthy | 343 | United States | clinicaltrials.gov |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 | clinicaltrials.gov | |
| November 5, 2026 | NCT07918677 | Food Supplement for Individuals With Polygenic Hypercholesterolaemia | ESI | Not applicable | Recruiting | Polygenic Hypercholesterolaemia | 60 | Italy | clinicaltrials.gov |
| November 5, 2026 | NCT07918625 | A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes | BrightGene Bio-Medical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Overweight or Obese Participants Without Diabetes | 160 | China | clinicaltrials.gov |
| November 5, 2026 | NCT07918560 | Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis | Brainfarma Industria Química e Farmacêutica S/A | Not applicable | Not yet recruiting | Atopic Dermatitis, Psoriasis | 42 | Brazil | clinicaltrials.gov |
| November 5, 2026 | NCT07918469 | A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and... | Avata Biosciences Holdings Ltd | Phase 1 | Not yet recruiting | Focal Onset Seizure | 44 | clinicaltrials.gov | |
| November 5, 2026 | NCT07918456 | A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B. | Jiangsu Chuangyuan Life Science and Technology Co., Ltd. | Phase 1 | Enrolling by invitation | Chronic Hepatitis B | 74 | China | clinicaltrials.gov |
| November 5, 2026 | NCT07918443 | Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VI | Croma-Pharma GmbH | Not applicable | Not yet recruiting | Moderate to Severe Midface Volume Deficit | 45 | clinicaltrials.gov | |
| November 5, 2026 | NCT07918404 | Safety and Tolerability of Fluticasone Propionate 10% Nasal Insert in Participants With Chronic Allergic Rhinitis | Dianosic | Phase 1 | Not yet recruiting | Chronic Allergic Rhinitis | 25 | clinicaltrials.gov | |
| November 5, 2026 | NCT07918001 | Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to... | IR INNOVATE RESEARCH PRIVATE LIMITED | Phase 4 | Recruiting | Acne | 225 | Vietnam | clinicaltrials.gov |
Sponsors posting most
| Sponsor | New trials | Latest |
|---|---|---|
| AstraZeneca | 327 | November 6, 2026 |
| Novartis Pharmaceuticals | 254 | November 6, 2026 |
| Pfizer | 217 | November 9, 2026 |
| Eli Lilly and Company | 198 | November 6, 2026 |
| Merck Sharp & Dohme LLC | 194 | November 6, 2026 |
| AbbVie | 154 | November 9, 2026 |
| Novo Nordisk A/S | 138 | November 5, 2026 |
| GlaxoSmithKline | 129 | November 4, 2026 |
| Bristol-Myers Squibb | 129 | October 21, 2026 |
| Sanofi | 126 | November 6, 2026 |
| Boehringer Ingelheim | 108 | November 9, 2026 |
| Hoffmann-La Roche | 102 | November 5, 2026 |
| Qilu Pharmaceutical Co., Ltd. | 92 | November 9, 2026 |
| Jiangsu HengRui Medicine Co., Ltd. | 84 | November 6, 2026 |
| Regeneron Pharmaceuticals | 74 | October 28, 2026 |
| Amgen | 69 | November 6, 2026 |
| Takeda | 65 | October 29, 2026 |
| Haisco Pharmaceutical Group Co., Ltd. | 63 | November 6, 2026 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 63 | September 25, 2026 |
| Janssen Research & Development, LLC | 62 | November 4, 2026 |
Conditions
| Condition group | New trials | Latest |
|---|---|---|
| Obesity | 527 | November 9, 2026 |
| Overweight | 384 | November 9, 2026 |
| Carcinoma, Non-Small-Cell Lung | 362 | November 9, 2026 |
| Diabetes Mellitus, Type 2 | 304 | November 6, 2026 |
| Breast Neoplasms | 254 | November 6, 2026 |
| Neoplasms | 236 | November 6, 2026 |
| Colorectal Neoplasms | 231 | November 3, 2026 |
| Dermatitis, Atopic | 175 | November 6, 2026 |
| Prostatic Neoplasms | 158 | October 30, 2026 |
| Ovarian Neoplasms | 149 | November 9, 2026 |
| Recurrence | 139 | November 6, 2026 |
| Neoplasm Metastasis | 138 | November 2, 2026 |
| Heart Failure | 136 | October 16, 2026 |
| Pulmonary Disease, Chronic Obstructive | 134 | November 9, 2026 |
| Lung Neoplasms | 128 | November 4, 2026 |
| Alzheimer Disease | 125 | October 29, 2026 |
| Pancreatic Neoplasms | 122 | November 2, 2026 |
| Diabetes Mellitus | 119 | November 4, 2026 |
| Lupus Erythematosus, Systemic | 118 | November 6, 2026 |
| Hypertension | 114 | November 5, 2026 |
| Multiple Myeloma | 112 | November 9, 2026 |
| Atrial Fibrillation | 105 | November 9, 2026 |
| Asthma | 102 | November 9, 2026 |
| Stomach Neoplasms | 102 | November 6, 2026 |
| Renal Insufficiency, Chronic | 100 | November 9, 2026 |
By phase
| Phase | New trials | Latest |
|---|---|---|
| Phase 1 | 3,570 | November 9, 2026 |
| Not applicable | 3,356 | November 9, 2026 |
| Observational | 2,276 | November 9, 2026 |
| Phase 2 | 2,090 | November 9, 2026 |
| Phase 3 | 2,047 | November 9, 2026 |
| Phase 1/2 | 1,084 | November 6, 2026 |
| Phase 4 | 330 | November 6, 2026 |
| Phase 2/3 | 225 | November 9, 2026 |
| Early phase 1 | 182 | October 29, 2026 |
Where the register publishes
U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.